Denali Therapeutics Inc. (DNLI)

NASDAQ: DNLI · IEX Real-Time Price · USD
20.52
-0.25 (-1.20%)
At close: Mar 28, 2024, 4:00 PM
20.54
+0.02 (0.08%)
After-hours: Mar 28, 2024, 6:17 PM EDT

Company Description

Denali Therapeutics Inc., a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States.

The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.

Its brain-penetrant small molecule programs comprise BIIB122/DNL151 LRRK2 inhibitor program for Parkinson's disease; SAR443820/DNL788 RIPK1 inhibitor program for CNS disease; DNL343 eIF2B Activator program for amyotrophic lateral sclerosis; and SAR443122/DNL758 RIPK1 inhibitor program for peripheral inflammatory diseases.

It also provides early stage program include TAK-594/DNL593 program for FTD-GRN; DNL126 program for MPS IIIA, a Sanfilippo Syndrome A; DNL622 for MPS I which is Hurler syndrome; Antibody Transport Vehicle Amyloid beta program; Oligonucleotide Transport Vehicle platform, a novel class of biotherapeutics to address the root cause of diseases through modulation of gene expression; and other TV-enabled discovery programs.

The company has collaboration agreements with Biogen MA Inc. and Biogen International GmbH; Genzyme Corporation; Takeda Pharmaceutical Company Limited; F-star Gamma Limited, F-star Biotechnologische Forschungs-und Entwicklungsges m.b.H, and F-star Biotechnology Limited; and Genentech, Inc. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015.

Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.

Denali Therapeutics Inc.
Denali Therapeutics logo
Country United States
IPO Date Dec 8, 2017
Industry Biotechnology
Sector Healthcare
Employees 445
CEO Dr. Ryan J. Watts Ph.D.

Contact Details

Address:
161 Oyster Point Blvd.
South San Francisco, California 94080
United States
Phone (650) 866-8548
Website denalitherapeutics.com

Stock Details

Ticker Symbol DNLI
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001714899
CUSIP Number 24823R105
ISIN Number US24823R1059
Employer ID 46-3872213
SIC Code 2836

Key Executives

Name Position
Dr. Ryan J. Watts Ph.D. Co-Founder, President, Chief Executive Officer and Director
Dr. Alexander O. Schuth M.D. Co-Founder, Chief Financial Officer, Chief Operating Officer and Secretary
Dr. Marc Tessier-Lavigne Ph.D. Co-Founder and Independent Director
Dr. Carole Ho M.D. Chief Medical Officer and Head of Development
Tyler M. Nielsen Senior Vice President of Corporate Finance
Dr. Dana Andersen Chief Technical and Manufacturing Officer
Joe Lewcock Ph.D. Chief Scientific Officer
Dr. Laura Hansen Vice President of Investor Relations
Chris Walsh General Counsel
Mark Rowen Vice President of Corporate Development

Latest SEC Filings

Date Type Title
Mar 22, 2024 S-3ASR Automatic shelf registration statement of securities of well-known seasoned issuers
Mar 1, 2024 D Notice of Exempt Offering of Securities
Feb 28, 2024 S-8 Securities to be offered to employees in employee benefit plans
Feb 28, 2024 10-K Annual Report
Feb 27, 2024 8-K Current Report
Feb 27, 2024 8-K Current Report
Feb 16, 2024 8-K Current Report
Feb 14, 2024 144 Filing
Feb 14, 2024 144 Filing
Feb 13, 2024 144 Filing